Biobijou
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Biobijou makes injectable skin-care products, including skin boosters and dermal fillers, which are gel-like substances injected to hydrate skin or smooth wrinkles, using hyaluronic acid and other materials.
Its products are used in cosmetic and medical-aesthetic procedures and are supplied to markets outside Korea, making it an export-focused business. Listed on KOSDAQ, Korea's tech and small-cap board, the company spans both the cosmeceutical (cosmetics with active ingredients) and medical-aesthetic segments of the global beauty industry.
Summary is AI-generated and may contain errors · figures from DART filings
Biobijou in five facts
What does Biobijou do?
Biobijou makes injectable skin-care products, including skin boosters and dermal fillers, which are gel-like substances injected to hydrate skin or smooth wrinkles, using hyaluronic acid and other materials.
Where is Biobijou listed and in which sector?
Biobijou (Korean name: 바이오비쥬) trades under KRX code 489460 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Materials sector, Chemicals.
How large is Biobijou?
Its market capitalisation was US$130.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Biobijou's latest annual revenue and operating profit?
For fiscal year 2025, Biobijou reported revenue of US$21.5M, operating profit of US$3.2M and net income of US$3.1M, per its annual report on DART (data retrieved from DART on 2026-06-04).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-04
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (abbreviated)Oct 2
- Securities issuance results (voluntary)Sep 18
- Material event report (convertible bonds)
Biobijou disclosed convertible bonds to raise US$44.5M, about 35.4% of its market value.
Capital raise · Sep 10 - Treasury share acquisition: results reportTreasury Shares · Jul 1
- Material event report (treasury share acquisition)
Biobijou disclosed a plan to buy back its own shares worth US$1.32M, about 1.2% of its market value.
Treasury Shares · Jun 1 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Biobijou reported consolidated results for FY2025: revenue of US$19.4M (−3.86% year on year), operating profit of US$2.87M (−54.19% year on year) and net income of US$2.28M (−53.41% year on year).
Earnings · Mar 13 - Cash/in-kind dividend decision
Biobijou declared a cash dividend of US$0.07 per share.
Dividend · Feb 12